aspandemicinfluenzaand/orCOVID-19.
cross-protectionagainstconstantlyevolvingvariantsiscritical,such
beextended to addressotheremerging infectious diseaseswhere
established and validated platform for vaccine manufacture could
impurities in vulnerable individuals are eliminated. This well-
egg-protein, and thus potential adverse reactions to these
related process-impurities such as inactivating agents or residual
the need for a viral inactivation step and avoids the use of eggs,
impurities are the hallmarks of RIV4. As rHA production bypasses
homogeneity of rHA rosettes and negligible process-related
together with the direct or indirect evidence supporting this. The
forthegenerationofbroadcross-reactiveandprotectiveantibodies,
featuresoftherHAtertiarystructurethatarelikelytoberesponsible
HA structure through egg- or cell-adaptation. We also describe
theriskofantigenicmismatchduetopotentialchangesinprimary
enrichment.Theuseofrecombinantproteintechnologyeliminates
ormammaliancells,splitwithdetergentswithorwithoutfurtherHA
in uenzavaccinesthatrelyonin uenzavirionspropagatedinegg